• Profile
Close

Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: Results from a phase 3 trial

Arthritis Research & Therapy Dec 10, 2018

Strand V, et al. - Authors evaluated the impact of abatacept treatment on patient-reported outcomes (PROs) in psoriatic arthritis (PsA). They randomized (1:1) patients with PsA to subcutaneous abatacept 125 mg weekly/placebo for 24 weeks with early escape (EE) to open-label abatacept (week 16). PROs were improved in patients with PsA with abatacept treatment vs placebo, with better results in elevated baseline CRP and TNFi-naïve subpopulations. They noted numerically greater PRO improvements in patients with baseline CRP > ULN vs CRP ≤ ULN at week 16.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay